

감각신경성 난청의 치료

가톨릭대학교 의과대학 이비인후과학교실
 전 범 조·여 상 원

Treatment of Sensorineural Hearing Loss

Beom Cho Jun, MD and Sang-Won Yeo, MD

Department of Otolaryngology, The Catholic University, Seoul, Korea

서 론

2)

, 3)

, 4)

, 5)

1)

면역억제요법

면역성 난청의 치료

(Immune - mediated hearing loss)

가 가

가 , Kanzaki ²⁾ 1 prednisone 30 mg
 3 5 mg 18~20

가

50%

. 1) 20~50 (),

2 McCabe³⁾
 : , 137 - 701 505 (initial treatment) cyclophosphamide 60 mg
 가 : (02) 590 - 1750, 2791 - : (02) 595 - 1354 12 , prednisone 30 mg 4
 E - mail : swyeo@catholic.ac.kr 가 (

:

3 15 dB G class
가 20% 가)
(full treatment) . 가
3 cyclophosphamide G (rapid equilibrium)
prednisone 2 2 가
. 3 (rebound phenomenon).⁶⁾
가 , G 가 ,

Harris⁴⁾ prednisone 1 60 mg 2 . Luetje ⁸⁾ 가
, (maintenance dose) 가 16
6~12 . 2 8 (50%)
가 cyclophosphamide 4 (25%)
가 . Harris⁵⁾ 가
(high dose steroid therapy)
prednisone 60 mg 4 , 세포독성 약제
1~2 가
10~20 mg . 가 , McCabe³⁾ prednisone cyclophosphamide
. cyclophosphamide 2~5 mg/kg
cyclophosphamide
(hemorrhagic cystitis), (urinary tract) ,
1 10 가
. 가
methotrexate가 가
. methotrexate dihydrofolate reductase (anti - metabolite agent)
DNA ,
B - , T - . methotrexate
second - line
. Sismanis ⁹⁾ 25
methotrexate
1 7.5 mg
2 85~90%, 3 12.5~15 mg(25 mg)
95% .⁷⁾ 가 6~

혈장만출(Plasmapheresis)

12 (13)
70% , 80%

8 methotrexate
Matteson
10) 17 가 15 dB
methotrexate 12
65% , 12%
23% 가 . me-
thotrexate
(interstitial fibrosis)
4 CBC,

치료결과판정

3
가 20%
good response ,
Kanzaki 2) 가 ice - water
caloric test

돌발성 난청의 치료

folic acid folate
11)

최신면역요법

가
oral tolerance therapy, (vaccination)
tumor
necrotic factor(TNF), intercellular adhesion mole-
cule - 1(ICAM - 1), CD4 가,
(multiple sclerosis) VLA - 4, gamma -
interferon(IFN -) 가

부신피질호르몬제

()
prednisone 60~80 mg(1 mg/kg/
day) 10~12

myelin basic protein(MBP) oral feeding
T - transforming growth factor -
beta(TGF -) IFN - TNF

12) Dalal 13)
experimental allergic
encephalitis(EAE) testosterone
EAE , Yeo 14)
testosterone
Testosterone 38%
T - IL - 10
가 Th1 down - regulate witz 16)

1
Wilson 15)
90 dB
placebo
90 dB
78%, placebo
, Mosko-

:
 Wilkins¹⁷⁾ carbogen 가 1 carbo-
 gen
 Redleaf²³⁾ diatrizoate dextran
 36 74%가
혈관 확장제 및 혈액순환 개선제
 가
 가
 Histamine 2.75 mg/day 500 ml
 30 3
 papaverine, nicotinic acid가 가
 niacin, procain . Fisch¹⁸⁾ novan²⁴⁾ . Schuknecht Do-
 carbogen gas mixture(5% CO₂, 95% O) 12 가
 가
 가 1
 8 30 carbogen Wilson²⁵⁾ 70% herpes in-
 . Donaldson¹⁹⁾ fection
 69.6% 가 latent herpes
 66% , Rahko Kotti²⁰⁾ carbogen virus 가
 heparin Acyclovir(Zovirax)가
 DHA
 . Acyclovir
 low molecular weight 800 mg 1 5 10 . herpes
 dextran, mannitol, pentoxifylline, heparin simplex type 1 2, cytomegalovirus, varicella-
 가 . low molecular weight dextran zoster virus, E - B virus human herpes
 virus valacyclovir가
²¹⁾ , , Tucci²⁶⁾ vala-
 . Pentoxifyphyline 400 cyclovir 가
 , 10% low molecular
 mg 1 3 , 3~7
 weight dextran 500 mL 1 4 5,000~
 heparin 12 2~3
 10,000 unit 가
 triiodinated benzoic acid diatrizoate
 (Hypaque)가 가
 diatrizoate 54%가
 19% .²²⁾ Diatrizoate
 . Fisch¹⁸⁾ papaverine dextran

면역억제제

antibodies)가 (cross - reacting 가
 가
 . Yeo
 28)29)
 가
 glucocorticoid, (cytotoxic
 agent)
 가
 Wilkins 17) , carbogen ,
 , , “shotgun
 regimen ” 1/3
 1/3 40~60 dB
 1/3 30)
 47~63% .
 가
 가
 40
 2
 1
 6 30)

중심 단어 :

REFERENCES

1) Hughes GB, Barna BP, Kinney SE, Calabrese LH, Nalepa NJ. *Clinical diagnosis of immune inner ear disease. Laryngoscope* 1988;98:251-3.

2) Kanzaki J, Toshiaki O. *Steroid-responsive bilateral sensorineural hearing loss and immune complexes. Arch Otorhinolaryngol* 1981;230:5-9.
 3) McCabe BF. *Autoimmune inner ear disease: therapy. Am J Otol* 1989;10:196-7.
 4) Harris JP. *Immunologic mechanisms in disorders of the inner ear. In Cummings CW, Their SO, editors, Otolaryngology-Head and Neck Surgery, 2nd ed., Mosby Year Book Inc.; 1994. p.2926-42.*
 5) Harris JP. *Immunologic disorders affecting the ear. In Cummings CW, Their SO, editors, Otolaryngology-Head and Neck Surgery, 2nd ed., Mosby Year Book Inc.;1998. p.3172-85.*
 6) Kennedy MS, Domen RE. *Therapeutic apheresis: application and future directions. Vox Sang* 1983;45:261-77.
 7) Silvergleid AJ. *Applications and limitations of hemapheresis. Annu Rev Med* 1983;34:69-89.
 8) Luetje CM, Berliner K. *Plasmapheresis in autoimmune inner ear disease: long-term follow-up. Am J Otol* 1997;18:572-6.
 9) Sismanis A, Wise CM, Johnson GD. *Methotrexate management of immune-mediated cochleovestibular disorders. Otolaryngol Head Neck Surg* 1977;116:146-52.
 10) Metteson EL, Fabry DA, Facer GW, Beatty CW, Driscoll CW, Strome SE, McDonald TJ. *Open trial of methotrexate as treatment for autoimmune hearing loss. Arthritis Care Research* 2001;45:146-50.
 11) Morgan SL, Baggot JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, Alarcon GS. *The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum* 1990;33:9-18.
 12) Steinman L. *Autoimmune Disease. Scientific American* 1993;269:107-14.
 13) Dalal M, Kim S, Vaskuhl R. *Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. J Immunol* 1997;159:3-6.
 14) Yeo SW, Chang KH, Park SN, Suh BD. *Effects of testosterone in the treatment of immune-mediated hearing loss. Eur Arch Oto-Rhino-Laryngol* 2003;260:316-9.
 15) Wilson WR, Byl FM, Laird N. *The efficacy of steroids in the treatment of idiopathic sudden hearing loss: A double-blind clinical study. Arch Otorhinolaryngol* 1980;106:772-6.
 16) Moskowitz D, Lee KJ, Smith HW. *Steroid use in idiopathic sudden sensorineural hearing loss. Laryngoscope* 1984;94:664-6.
 17) Wilkins SA Jr, Mattox DE, Lyles A. *Evaluation of a “shotgun” regimen for sudden hearing loss. Otolaryngol Head Neck Surg* 1987;97:474-80.
 18) Fisch U. *Management of sudden deafness. Otolaryngol Head Neck Surg* 1983;91:3-8.
 19) Donaldson JA. *Heparin therapy for sudden sensorineural hearing loss. Arch Otorhinolaryngol* 1979;105:351-2.
 20) Rahko T, Kotti V. *Comparison of carbogen inhalation and intravenous heparin infusion therapies in idiopathic sudden sensorineural hearing loss. Acta Otolaryngol (Stockh)* 1997;

- :
- Suppl* 529:86-7.
- 21) Hulterantz E, Stenquist M, Lyttkens L. *Sudden deafness: a retrospective evaluation of dextran therapy. ORL J Otorhinolaryngol Relat Spec* 1994;56:137-42
 - 22) Morimitsu T. *Dysfunction of stria vascularis as a new theory of sudden deafness. Adv Otorhinolaryngol* 1977;22: 57-75.
 - 23) Redleaf MI, Bauer CA, Gantz BJ, Hoffman HT, McCabe BF. *Diatrizoate and dextran treatment of sudden sensorineural hearing loss. Am J Otol* 1995;16:295-303.
 - 24) Schknecht HF, Donovan ED. *The pathology of idiopathic sudden sensorineural hearing loss. Arch Otorhinolaryngol* 1986;243:1-15.
 - 25) Wilson WR. *The relationship of the herpesvirus family to sudden hearing loss: a prospective clinical study and literature review. Laryngoscope* 1986;96:870-7.
 - 26) Tucci DL, Farmer JC Jr, Kitch RD, Witsell DL. *Treatment of sudden sensorineural hearing loss with systemic steroids and valacyclovir. Otol Neurotol* 2002;23:301-8.
 - 27) Hughes GB. *Sudden sensorineural hearing loss. Otolaryngol Clin North Am* 1996;29:393-413.
 - 28) Yeo SW, Chang KH, Suh BD, Kim TG, Han H. *Distribution of HLA-A, -B and -DRB1 alleles in patients with sudden sensorineural hearing loss. Acta Otoaryngologica (Stockh).* 2000;120:710-5.
 - 29) Yeo SW, Park SN, Park YS, Suh BD, Han H, Choi HB, Kim TG. *Different distribution of HLA class II alleles according to response to steroid therapy in sudden sensorineural hearing loss. Arch Otolaryngol Head Neck Surg* 2001;127:945-9.
 - 30) Yoon TH, Paparella MM, Schachern PA, Alleva M. *Histopathology of sudden hearing loss. Laryngoscope* 1990;100: 707-15.